Pharmaceutical product development technologies based on the biopharmaceutical classification system

Pharmazie

Volumn 64, Issue 8, 2009, Pages 483-490

  Jain, D ^a   Pathak, Deepa ^a   Pathak, K ^a  

^a NH 2   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATENOLOL; BIOERODABLE ENHANCED ORAL DRUG ABSORPTION SYSTEM; BIORISE; BIOSILICON; CAP; CAPTOPRIL; CARBAMAZEPINE; CIMETIDINE; CODAS; CYCLOSPORIN; DESIPRAMINE; DICLOFENAC; DILTIAZEM; DUAL RELEASE DRUG ABSORPTION SYSTEM; ENALAPRIL; FAMOTIDINE; FLURBIPROFEN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INSOLUBLE DRUG ABSORPTION SYSTEM; INSOLUBLE DRUG DELIVERY; INTESTINAL PROTECTIVE DRUG ABSORPTION SYSTEM; ITRACONAZOLE; KETOPROFEN; LABETALOL; LEVODOPA; LOCALIZED DRUG ABSORPTION SYSTEM; METOPROLOL; MULTIPOROUS ORAL DRUG ABSORPTION SYSTEM; NADOLOL; NANOCRYSTAL; NANOEDGE; NANOGATE; NANOPARTICLE ALBUMIN BOUND; NANOZOME; NAPROXEN; NIFELAN; NLC 8; PHARMAZOME; PHENAZONE; PHENYLALANINE; PHENYTOIN; PIROXICAM; PROGRAMMABLE ORAL DRUG ABSORPTION SYSTEM; PROPRANOLOL; RANITIDINE; SMART PILL; SPHEROIDAL ORAL DRUG ABSORPTION SYSTEM; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; DRUG;

DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG COST; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; REVIEW; TECHNOLOGY; ANIMAL; CLASSIFICATION; HUMAN; INTESTINE ABSORPTION; NANOTECHNOLOGY; PHARMACEUTICS; PHARMACOKINETICS;

ANIMALS; BIOPHARMACEUTICS; HUMANS; INTESTINAL ABSORPTION; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 70349757519     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8040     Document Type: Review

References (16)

1. Avdeef A (2001) Physicochemical profiling (solubility, permeability and charge state) (2001) Curr Topic Med Chem: 277-351.
2. Betlach CJ, Arnold JD, Frost RW, Leese PT, Gonzalez MA (1987) Bioavailability and Pharmacokinetics of a New Sustained-Release Potassium Chloride Tablet. Pharm Res 4 : 409-411.
3. Chang KC, Cherng WJ (1998) Once-daily nifedipine sustained release (nifelan) on forearm vascular resistance and regression of left ventricular hypertrophy in patients with mild to moderate essential hypertension. Med J 21: 28-36.
4. Dressman JB, Reppas C (2000) In vitro - In vivo correlation for lipophilic poorly water soluble drugs. Eur J Pharm Sci 11: 73-80.
5. Dressman J, Butler J, Hempenstall J, Reppas C (2001) The BCS: Where do we go from here? Pharm Technol: 68-76.
6. Devane J (1998) Oral drug delivery technology: Addressing the solubility/ permeability paradigm. Pharm Technol: 68-80.
7. TM technology to Aventis.
8. Gaston G (1996) A double-blind randomized, parallel-group study of the pharmacokinetics and onset of action of naprelan in patients following oral surgery. Am J Orthop 25: 37-41.
9. Grove CF (2007) www. Freepatent.com.
10. Löbenberg GL, Amidon R (2000) Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50: 3-12.
11. Saffie-Siebert R, Ogden J, Parry-Billings M (2005) Drug Discovery World Summer: 71-76.
12. Shah PV, Amidon LG, Lennernas H, Crison RJ (1995) A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro product dissolution and in vivo bioavailability. Pharma Res 3: 413-420.
13. Savard D, Lenis J, Juneau M, Jacob C (1995) Clinical efficacy and safety of once-daily diltiazem in patients with stable angina. J Cardiovasc Pharmacol 26: 85-9.
14. Verma S, Garg RK (2001) Current status of drug delivery technologies and future directions. Pharm Technol 25: 1-14.
15. Waterbeemd HVD (1998) The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur J Pharm Sci 7: 1-3.
16. Wrenn Jr, Simeon M, Danville CA (1998) Oral administration of adenosine analogs. United States Patent: 6,174,873.